Aurobindo Pharma, Divi's Laboratories Limited and BASF SE are Dominating In The Global API Intermediates Market in 2020

Global API Intermediates Market is expected to grow with the CAGR of 6.4% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @

Global API intermediates market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in global API intermediates market are introducing strong range of products providers along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This has helped the companies to maximize the sales with enhanced product portfolio.

For instance,

  • in January 2021, Aurobindo Pharma has received approval for financial support from the central government as per the PLI scheme (production linked incentive). The company has received this financial support for accelerating the production of starting materials, intermediates among others. This approval and support boosted the company’s manufacturing skills.

Aurobindo Pharma is the dominating player in global API intermediates market. The other key players existing in the API intermediates market are HIKAL Ltd., Cambrex Corporation, Ganesh-Group, AlzChem Group AG, Vasudha Pharma, Anyang General Chemical Co.,Ltd., Sarex, Sandoo Pharmaceuticals and Chemicals Co., Ltd., Atul Ltd, Sandoz International GmbH (a subsidiary of Novartis AG), Aceto, Supriya Lifescience Ltd., LEVACHEM COMPANY LIMITED, Vertellus, Dishman Carbogen Amcis Ltd, Sanofi, Divi's Laboratories Limited, AARTI INDUSTRIES LIMITED and BASF SE among others.

API Intermediates Market

Aurobindo Pharma:

Aurobindo Pharma is headquartered in Telangana, India and was founded in 1986. The company is focused on continuous research, development and production of pharmaceutical products that meets the regulatory standards. The company deals in multiple business segments along with it provides products under several categories including formulations, custom synthesis, peptides, aurozymes, API and R&D in which API is the market focused segment and category.

For instance,

  • In November 2019, Aurobindo Pharma received EIR from the U.S. healthcare regulator. The company has received EIR for its Hyderabad pharmaceutical manufacturing unit. This approval demonstrated the company’s satisfactory manufacturing abilities. This approval enhanced the company’s product manufacturing abilities.

The company has wide presence across North America, Asia-Pacific, Europe, Middle East and Africa and South America. The company also has various subsidiary companies including Aurobindo Pharma USA, Inc. (U.S.), Actavis Deutschland GmbH & Co. KG (Dublin), APL Research Centre Limited (Hyderabad), Aurolife Pharma (U.S.), Auro Peptides Limited (Hyderabad) among others.

Divi's Laboratories Limited:

Divi's Laboratories Limited is headquartered in Hyderabad, India and was founded in the 1990. The company is focused on the production of high quality products such as generic APIs, custom synthesis of APIs & intermediates and also deals with the nutraceuticals. The company operates its business via two business segments including pharmaceuticals and crop protection in which pharmaceuticals is the market focused segment. The company has wide products under categories which are generic APIs, custom synthesis and nutraceuticals in which custom synthesis is the market focused category.

For instance,

  • In 2018, Divi's Laboratories Limited had received certificate of Occupational Health and Safety Management system from Bureau Veritas Quality International. The company has received this certification for its outstanding product manufacturing practices. This certification enhanced the company’s value and allowed it to attain a lucrative growth.

The company has presence across the U.S., Europe and India. The company also has various subsidiaries including Divi’s Laboratories Europe AG (Europe), Divis Laboratories (USA), Inc. (U.S.) and others.


BASF SE is headquartered in Ludwigshafen, Germany and was founded in the 1865. The company is focused on providing the high quality products and solutions by using the best resources and create a better future for the world by facing challenges. The company operates its business through multiple segments including chemicals, materials, industrial solutions, surface technologies, nutrition & care and agriculture solutions in which nutrition & care is the market focused segment. The company has various products under categories that are agriculture, automotive & transportation, chemicals, construction, electronics & electric, energy & resources, furniture & wood, home care and industrial & institutional cleaning solutions, nutrition, packaging & print, personal care & hygiene, pharmaceuticals, plastic & rubber, leather and footwear & textile in which pharmaceuticals is the market focused category.

For instance,

  • In June 2017, BASF SE announced for the opening of new manufacturing plant for ibuprofen in Germany. This initiative boosted the company’s ibuprofen production and also accelerated the production of ibuprofen intermediates. This plant considered to be the one of the biggest plant for ibuprofen. This initiative allowed the company to get recognized as one of the leading manufacturer of ibuprofen which has positively impacted the company’s revenue.   

The company has presence across Europe, Americas, Asia-Pacific and Middle East and Africa. The company has various subsidiaries including BASF Coatings GmbH (Germany), Wintershall (Kassel, Germany), BASF Japan (Japan), Cognis (Germany), BASF Polyurethanes GmbH (Germany) among others.